BR100 Increased By (0.99%)
BR30 Increased By (1.17%)
KSE100 Increased By (0.81%)
KSE30 Increased By (0.77%)
BECO 5.68 Increased By ▲ 0.09 (1.61%)
BML 64.84 Increased By ▲ 3.81 (6.24%)
BOP 33.60 Increased By ▲ 0.35 (1.05%)
CNERGY 8.24 Increased By ▲ 0.19 (2.36%)
DCL 11.35 Increased By ▲ 0.05 (0.44%)
FCCL 52.91 Decreased By ▼ -0.02 (-0.04%)
FCSC 5.52 Increased By ▲ 0.18 (3.37%)
FFL 17.80 Increased By ▲ 0.19 (1.08%)
FNEL 1.30 Decreased By ▼ -0.01 (-0.76%)
HUMNL 11.24 Increased By ▲ 0.12 (1.08%)
KEL 7.97 Increased By ▲ 0.08 (1.01%)
KOSM 5.44 Increased By ▲ 0.11 (2.06%)
MLCF 86.01 Increased By ▲ 0.66 (0.77%)
NBP 185.00 Increased By ▲ 3.71 (2.05%)
PACE 12.02 Increased By ▲ 0.49 (4.25%)
PAEL 40.21 Increased By ▲ 0.80 (2.03%)
PIAHCLA 25.73 Increased By ▲ 0.10 (0.39%)
PIBTL 17.32 Increased By ▲ 0.17 (0.99%)
PPL 225.30 Increased By ▲ 0.48 (0.21%)
PRL 34.38 Increased By ▲ 0.20 (0.59%)
PTC 65.46 Increased By ▲ 0.38 (0.58%)
SEARL 90.51 Increased By ▲ 0.91 (1.02%)
SSGC 26.76 Increased By ▲ 0.45 (1.71%)
TELE 8.96 Increased By ▲ 0.58 (6.92%)
THCCL 69.44 Increased By ▲ 0.10 (0.14%)
TPLP 11.31 Increased By ▲ 1.03 (10.02%)
TREET 24.55 Increased By ▲ 0.35 (1.45%)
TRG 71.67 Increased By ▲ 2.13 (3.06%)
WAVES 11.45 Increased By ▲ 0.42 (3.81%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
Topic

Novavax

Australia's CSL unable to simultaneously make Novavax, AstraZeneca vaccines

Australia's CSL unable to simultaneously make Novavax, AstraZeneca vaccines

Published 20 May, 2021 06:11pm
  • Australian biotech CSL is already under contract to locally make 50 million doses of the AstraZeneca vaccine, and is currently churning out more than a million doses a week.
  • Australia is relying on deliveries from Pfizer after restricting the use of AstraZeneca's shot in April in people below 50 years due to rare blood-clotting cases.
South Korea signs with Pfizer for additional 40mn COVID-19 vaccine doses

South Korea signs with Pfizer for additional 40mn COVID-19 vaccine doses

Published 24 Apr, 2021 05:58pm
  • It added that it had secured a total 192 million doses of vaccines, including those from Moderna Inc, AstraZeneca PLC, Johnson & Johnson's and Novavax.
  • "The government has acquired COVID-19 vaccines large enough to vaccinate approximately 100 million people...(which) is double the entire population of South Korea," Health Minister Kwon Deok-cheol told a briefing.
Indian shares rebound

Indian shares rebound

Published 14 Apr, 2021 03:21am
BENGALURU: Indian shares ended more than 1% higher on Tuesday after the government moved to fast-track approvals for...
Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial

Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial

Updated 12 Mar, 2021 04:07pm
  • There were no cases of severe illness or deaths among those who got the vaccine, the company said.
  • The vaccine was 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom, for a combined 90% effectiveness rate overall based on data from infections of both versions of the coronavirus.
Rich nations stockpiling a billion more COVID-19 vaccine shots than needed: Report

Rich nations stockpiling a billion more COVID-19 vaccine shots than needed: Report

Updated 19 Feb, 2021 02:55pm
  • In an analysis of current supply deals for COVID-19 vaccines, the ONE Campaign said wealthy countries, such as the United States and Britain, should share the excess doses to “supercharge” a fully global response to the pandemic.
  • On Thursday, the World Health Organization urged nations with vaccines not to share them unilaterally, but to donate them to the global COVAX scheme to ensure fairness.
EU close to vaccine supply deal with Novavax

EU close to vaccine supply deal with Novavax

Published 11 Feb, 2021 08:29pm
  • "Talks with Novavax have intensified and we aim to agree the contract this week or next," one EU official said.
  • Novavax said negotiations were ongoing. A spokesman for the EU Commission declined to comment on the talks.
Loading...